SMO V321M

CI-VAR-00004519Explore in graph →CIViC 1576

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Basal Cell Carcinoma3
SMO V321M	Vismodegib	Predictive	C	Supports Resistance	—	submitted	EID4660 In a basal cell carcinoma (BCC) patient harboring PTCH1 inactivating alterations (known to be sensitizing to vismodegib treatment) and a SMO V321M mutation, SMO V321M was associated with acquired resi… (full text at CIViC) PMID 25199678 · Brinkhuizen et al., 2014 · Open in CIViC	civic
SMO V321M	Vismodegib	Predictive	D	Supports Resistance	—	submitted	EID4661 In an in vitro study, mouse embryonic fibroblasts (MEFs), null for the Smo mouse gene expressing SMO V321M mutation, demonstrated resistance to vismodegib treatment (IC50: >320 nmol/L vs. 8.23 nmol/L)… (full text at CIViC) PMID 25759020 · Atwood et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.